Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Voydeya danicopan Paroxysmal nocturnal hemoglobinuria (PNH) Active
VPRIV Velaglucerase alfa Gaucher Disease List with clinical criteria and/or conditions Complete
Vraylar cariprazine Bipolar Disorder Do not reimburse Complete
Vraylar cariprazine Schizophrenia Do not reimburse Complete
Vraylar cariprazine Schizophrenia Reimburse with clinical criteria and/or conditions Active
Vyalev foslevodopa foscarbidopa Parkinson's disease Reimburse with clinical criteria and/or conditions Complete
Vyepti eptinezumab Migraine Reimburse with clinical criteria and/or conditions Complete
Vyndaqel tafamidis Transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Vyndaqel tafamidis transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Vyvanse Lisdexamfetamine dimesylate Attention deficit hyperactivity disorder Do not list Complete